Gumball,
You and I are on the same page.
One slight difference though.
For a company like HEPI, at minimum, a major, Zoetis, has seen enough positive results from HEPI to pass the "sniff test" by their own scientists and request an exclusive look and collaboration to round out the dataset for a license. A cheap option for Zoetis before committing to a full development program. Scams and "total farce" POS companies don't get even that far. The bovine target is massive. Globally, well into the BILLIONS. So if Zoetis steps to the table to license from HEPI, it is huge. And it is all a huge IF. So you place your bet, or you don't.
Don't forget canine. In reviewing canine, it almost seems like canine license will come first. 3 different tests going to finalize that dataset and the target is the supplement arena. Much lower barriers to entry there. And HEPI's PRs indicate there is/are potential partners looking at this. I am hoping that another large player in the industry gets involved. The canine license does not have the scope of bovine but it could still bring significant money.
So it isn't quite the all or nothing you described. But it is still certainly a gamble. 15 cents is your downside. Upside is ????
Amigo Mike
News 
Market Data 
Discover 
